Invitae Corporation Stock Price, News & Analysis

Invitae (NYSE: NVTA) announced the appointment of Roxi Wen as chief financial officer, effective June 21, 2021. Wen brings extensive experience from her previous roles at Mozilla and General Electric, enhancing Invitae's financial leadership. Current CFO Shelly Guyer will focus on the company's ESG initiatives after guiding significant revenue growth from $400 million to over $6 billion. The appointment aligns with Invitae's goal to improve healthcare through comprehensive genetic information.

Invitae Corporation (NYSE: NVTA) has launched early access to its Personalized Cancer Monitoring (PCM™) platform, a lab-developed test aimed at detecting circulating tumor DNA (ctDNA) earlier than conventional methods, thereby enhancing cancer recurrence detection. This innovative service combines tumor profiles, blood tests, and personalized assays. Invitae aims for full commercial availability later this year, with the platform significantly validating its sensitivity and specificity for detecting minimal residual disease (MRD), which could improve patient outcomes and treatment adjustments.

Invitae Corporation (NYSE: NVTA) presented studies at the 2021 ASCO Annual Meeting highlighting the benefits of germline genetic testing for cancer patients. The research showed that all cancer types can benefit from genetic testing, which can guide treatment plans and increase eligibility for precision therapies. Notably, nearly one in six pancreatic cancer patients showed genetic changes linked to cancer, improving survival rates. However, current adoption of testing remains low, with only 3% of colorectal cancer patients receiving tests despite existing recommendations.

Invitae Corporation (NYSE: NVTA), a leader in medical genetics, will present at the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 3:20 p.m. Central (4:20 p.m. Eastern). The live webcast can be accessed via the company's investor website. Invitae aims to integrate comprehensive genetic information into mainstream medicine, improving healthcare quality. Their mission focuses on aggregating genetic tests for better quality, faster turnaround, and lower costs. For more, visit invitae.com.

Invitae Corporation (NYSE: NVTA) reported strong first-quarter results for 2021, achieving a revenue of $103.6 million, up 61% from $64.2 million year-over-year. Billable volume rose 72% to 259,000 tests, with an average cost per unit of $290. Despite a net loss of $109.5 million and total operating expenses of $140.5 million, cash and cash equivalents increased to $681.9 million. The company expanded its lab capacity in North Carolina and acquired Genosity and One Codex. Invitae also formed partnerships to enhance genetic testing accessibility.

Invitae Corporation (NYSE: NVTA) announced plans to open a new laboratory and production facility in North Carolina on April 20, 2021. This facility will cover 250,000 square feet and is expected to create over 350 jobs, enhancing Invitae's capacity to meet rising global demand for genetic testing services. The project is supported by a Job Development Investment Grant (JDIG). The new location aims to leverage the state's vibrant life sciences community and is intended to significantly increase the company's testing capabilities.

Invitae Corporation (NYSE: NVTA) will announce its first quarter 2021 financial results on May 4, 2021, followed by a conference call at 4:30 p.m. Eastern. The call will highlight financial results and recent company developments. Participants need to register for the call to receive details and a registrant ID. A live webcast and slide deck will be available, with a replay accessible post-event. Invitae aims to integrate genetic information into mainstream medicine to enhance healthcare quality globally.

The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NYSE: NVTA) to its coalition. This expansion reflects a commitment to advocate for coverage of comprehensive genomic profiling (CGP) for patients with advanced cancer. CGP testing aids medical management and improves clinical outcomes. ACGP aims to educate health insurers about the clinical utility of CGP. Invitae, a leader in medical genetics, seeks to provide comprehensive genetic information for better healthcare.

Invitae Corporation (NYSE: NVTA) announced research revealing that 15.5% of colorectal cancer patients have genetic changes significantly raising cancer risk, particularly in those diagnosed at a younger age. The study, presented at the 2021 ACMG Annual Clinical Genetics Meeting, evaluated genetic testing in 361 patients, finding mutations linked to increased cancer susceptibility. The results emphasize the need for advanced screening strategies and highlight the role of genetic testing in informing treatment decisions and family risk assessments.